Product Images Venlafaxine Hydrochloride ER

View Photos of Packaging, Labels & Appearance

Product Label Images

The following 7 images provide visual information about the product associated with Venlafaxine Hydrochloride ER NDC 80425-0290 by Advanced Rx Pharmacy Of Tennessee, Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.

Description - Description

Description - Description

The text is not-available.*

label 1 - Venlafazine HCL ER 80425 0290 01

label 1 - Venlafazine HCL ER 80425 0290 01

This is a medication called Venlafaxine HCL ER 37.5mg capsule. The package comes with 30 capsules and the National Drug Code (NDC) is 0425-0250:01. The source NDC is 42806-0601-09. There is a lot number mentioned as o0 with an expiry date of 3/23/3031. The numbers next to the lot number could be a serial number.*

label 2 - Venlafazine HCL ER 80425 0290 02

label 2 - Venlafazine HCL ER 80425 0290 02

label 3 - Venlafazine HCL ER 80425 0290 03

label 3 - Venlafazine HCL ER 80425 0290 03

This is a description of a medication package containing 90 capsules of Venlafaxine HCL ER with a strength of 37.5mg. The expiration date is indicated as 3723/3033.*

fig 1 - fig 1

fig 1 - fig 1

This text appears to be a list of drug interactions with certain medications, particularly CYP2D6 and CYP206 enzymes. The listed drugs include ethanol, diazepam, cimetidine, ketoconazole, indinavir, imipramine, lithium, and venlafaxine. Some drugs are recommended to avoid concomitant use, while others suggest using with caution or no dose adjustment. Clinical significance is unknown for some of the drugs. There is also a reference to PK Fold Change and 90% Cl Recommendation related to Cmax, and a number sequence listed under "Change relative to the reference value".*

fig 2 - fig 2

fig 2 - fig 2

This appears to be a list of drugs and their potential interactions or effects on the body, as well as their recommended dosages or precautions. However, without more context, it is difficult to determine its specific purpose or audience.*

fig 3 - fig 3

fig 3 - fig 3

This is a list of special populations with varying degrees of hepatic and renal impairments, CYP206 polymorphism, age, and gender that may affect the metabolism of specific analytes such as enlafaxine, enlataxine, and eniataine. The fold change and 90% CI are provided, along with recommendations for dose adjustments or individualization of dosing.*

* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.